Premium
Colestipol tablets in adolescents with familial hypercholesterolaemia
Author(s) -
Tonstad S,
Ose L
Publication year - 1996
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1996.tb14221.x
Subject(s) - medicine , palatability , pediatrics , pathology
The objective of this study was to examine palatability and side effects of the new tablet formulation of colestipol. A clinical series of 23 boys and 4 girls aged 10‐16 years with heterozygous familial hypercholesterolaemia were given 2‐12 g colestipol daily for 6 months in an open study. There were no serious side effects. The median reduction in low density lipoprotein cholesterol level was 20%. All preferred the tablets to resin granules they had tried previously. We conclude that low‐dose colestipol tablets appear to be safe and effective, and are preferred by adolescents.